Beams of $^{4}$He and $^{16}$O nuclei are considered for ion-beam cancer therapy as alternative options to protons and $^{12}$C nuclei. Spread-out Bragg peak (SOBP) distributions of physical dose and relative biological effectiveness for 10% survival
are calculated by means of our Geant4-based Monte Carlo model for Heavy Ion Therapy (MCHIT) and the modified microdosimetric kinetic model. The depth distributions of cell survival fractions are calculated for $^{1}$H, $^{4}$He, $^{12}$C and $^{16}$O for tissues with normal (HSG cells), low and high radiosensitivity. In each case the cell survival fractions were compared separately for the target volume, behind and in front of it. In the case of normal radiosensitivity $^{4}$He and $^{12}$C better spare tissues in the entrance channel compared to protons and $^{16}$O. The cell survival fractions calculated, respectively, for the entrance channel and target volume are similar for $^{4}$He and $^{12}$C. When it is important to spare healthy tissues located after the distal edge of the SOBP plateau, $^{4}$He can be recommended due to reduced nuclear fragmentation of these projectiles. No definite advantages of $^{16}$O with respect to $^{12}$C were found, with the except of an enhanced impact of these heavier projectiles on radioresistant tumors.
A Geant4-based Monte Carlo model for Heavy-Ion Therapy (MCHIT) is used to study radiation fields of H-1, He-4, Li-7 and C-12 beams with similar ranges (~160-180 mm) in water. Microdosimetry spectra are simulated for wall-less and walled Tissue Equiva
lent Proportional Counters (TEPCs) placed outside or inside a phantom, as in experiments performed, respectively, at NIRS, Japan and GSI, Germany. The impact of fragmentation reactions on microdosimetry spectra is investigated for He-4, Li-7 and C-12, and contributions from nuclear fragments of different charge are evaluated for various TEPC positions in the phantom. The microdosimetry spectra measured on the beam axis are well described by MCHIT, in particular, in the vicinity of the Bragg peak. However, the simulated spectra for the walled TEPC far from the beam axis are underestimated. Relative Biological Effectiveness (RBE) of the considered beams is estimated using a modified microdosimetric-kinetic model. Calculations show a similar rise of the RBE up to 2.2-2.9 close to the Bragg peak for helium, lithium and carbon beams compared to the modest values of 1-1.2 at the plateau region. Our results suggest that helium and lithium beams are also promising options for cancer therapy.
We model the responses of Tissue-Equivalent Proportional Counters (TEPC) to radiation fields of therapeutic C-12 beams in a water phantom and to quasi-monoenergetic neutrons in a PMMA phantom. Simulations are performed with the Monte Carlo model for
Heavy Ion Therapy (MCHIT) based on the Geant4 toolkit. The shapes of the calculated lineal energy spectra agree well with measurements in both cases. The influence of fragmentation reactions on the TEPC response to a narrow pencil-like beam with its width smaller than the TEPC diameter is investigated by Monte Carlo modeling. It is found that total lineal energy spectra are not very sensitive to the choice of the nuclear fragmentation model used. The calculated frequency-mean lineal energy y_f differs from the data on the axis of a therapeutic beam by less than 10% and by 10-20% at other TEPC positions. The validation of MCHIT with neutron beams gives us confidence in estimating the contributions to lineal energy spectra due to secondary neutrons produced in water by C-12 nuclei. As found, the neutron contribution at 10 cm distance from the beam axis amounts to ~ 50% close the entrance to the phantom and decreases to ~ 25% at the depth of the Bragg peak and beyond it. The presented results can help in evaluating biological out-of-field doses in carbon-ion therapy.
